跳至主要内容
临床试验/ITMCTR2100004503
ITMCTR2100004503招募中1 期

A multicenter randomized controlled clinical study of Qishao Tianxin prescription in the treatment of early urinary incontinence after radical prostatectomy for prostate cancer.

Beijing Chaoyang Hospital, Capital Medical University0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
55 至 75(—)
性别
All

入选标准

  • From January 2020 to June 2023, patients aged 55-75 who are prepared for radical resection of prostate cancer are mainly middle-to-high-risk prostate cancer patients:
  • (1) PSA >= 10; Or 4<=PSA<=10 and F/T < 0.16;
  • (2) TNM stage of prostate cancer >= T2 stage;
  • (3) Gleason score >= 7 points;Or the puncture Gleason score of both lobes >= 6 points at the same time; informed and agreed to participate in the clinical trial; able to cooperate with the treatment and complete the follow-up.

排除标准

  • Patients with heart, brain and lung diseases or liver and renal insufficiency.

研究者

发起方
Beijing Chaoyang Hospital, Capital Medical University

相似试验

A multicenter randomized controlled clinical study... | 临床试验